Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS
1 مناظر
• 07/16/23
0
0
ایمبیڈ
administrator
سبسکرائبرز
Visit http://www.ecancer.org for more
Prof Margolese (The Jewish General Hospital, McGill University, Montreal, Canada) talks to ecancertv at ASCO 2015 about a federally funded phase III trial that suggests postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.
مزید دکھائیں
فیس بک کے تبصرے
SORT BY-
سرفہرست تبصرے
-
تازہ ترین تبصرے